Participant flow

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas · Source last updated 2023-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Revlimid + rituximab with dexamethasone

   id

   FG000

   title

   Cohort 1

2. description

   Revlimid + rituximab (without dexamethasone)

   id

   FG001

   title

   Cohort 2

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         27

      2. group Id

         FG001

         num Subjects

         23

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         27

      2. group Id

         FG001

         num Subjects

         23

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice